Poynard Thierry, Munteanu Mona, Ratziu Vlad, Benhamou Yves, Di Martino Vincent, Taieb Julien, Opolon Pierre
Service d'Hépato-Gastroentérologie, Groupe Hospitalier Pitié-Salpêtrière, 47-83 Boulevard de l'Hôpital, 75651 Paris Cedex 13, France.
Ann Intern Med. 2002 Jun 18;136(12):888-95. doi: 10.7326/0003-4819-136-12-200206180-00010.
Factors associated with the survival of truth of clinical conclusions in the medical literature are unknown. The authors hypothesized that conclusions derived from studies using better methodology should have a longer half-life.
MEDLINE and hand searches of journals with studies on cirrhosis and hepatitis.
Original articles and meta-analyses published from 1945 to 1999 about cirrhosis or hepatitis in adults.
In 2000, 285 of 474 conclusions (60%) were still considered to be true, 91 (19%) were considered to be obsolete, and 98 (21%) were considered to be false. The half-life of truth was 45 years. The 20-year survival of conclusions derived from meta-analysis was lower (57% +/- 10%) than that from nonrandomized studies (87% +/- 2%) (P < 0.001) or randomized trials (85% +/- 3%) (P < 0.001). The survival of conclusions was not different when studies of high methodologic quality were compared with those of low quality. In randomized trials, the 50-year survival rate was higher for 52 negative conclusions (68% +/- 13%) than for 118 positive conclusions (14% +/- 4%) (P < 0.001).
Contrary to the authors' hypothesis, conclusions based on recognized, good methodology had no clear survival advantage. To better convince clinicians of the long-term utility of evidence-based medicine, better prognostic factors should be developed.
医学文献中临床结论真实性的存活相关因素尚不清楚。作者推测,采用更好方法学的研究得出的结论应具有更长的半衰期。
MEDLINE以及对手册中有关肝硬化和肝炎研究的期刊进行检索。
1945年至1999年发表的关于成人肝硬化或肝炎的原创文章和荟萃分析。
2000年,474条结论中有285条(60%)仍被认为是正确的,91条(19%)被认为过时,98条(21%)被认为错误。真实性的半衰期为45年。荟萃分析得出的结论的20年生存率(57%±10%)低于非随机研究(87%±2%)(P<0.001)或随机试验(85%±3%)(P<0.001)。将高质量研究与低质量研究的结论生存率进行比较时,并无差异。在随机试验中,52条阴性结论的50年生存率(68%±13%)高于118条阳性结论(14%±4%)(P<0.001)。
与作者的假设相反,基于公认的良好方法学得出的结论没有明显的存活优势。为了更好地使临床医生相信循证医学的长期效用,应制定更好的预后因素。